A Global Comparison Between Brand-Name and Generic Drugs

Chawla, Karan; Tofighi, Taraneh; Agarwal, Arnav; Thomas, Jason; Mondal, Tapas

doi:10.5530/ijopp.7.3.6

Cited by 6 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The implementation of specific regulations to encourage the production and use of generic drugs around the world occurred at different times and in different ways [ 76 ]. Likewise, interest in academic research related to the intention to purchase generic drugs also varied from country to country.…”

Section: Resultsmentioning

confidence: 99%

“…Likewise, interest in academic research related to the intention to purchase generic drugs also varied from one country to another, especially the United States and India. This insight also highlighted that these two countries are considered mature pharmaceutical markets due to the time that has elapsed since sector-specific regulations were implemented [ 76 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Attitude and Purchase Intention to Generic Drugs

Arcaro

Veiga

Silva

et al. 2021

IJERPH

View full text Add to dashboard Cite

Generic drugs were instituted in 1984 in the United States. Since that time, many studies have been conducted in several countries into consumer attitude and behavior when purchasing generic drugs. Understanding the factors that can influence attitude and purchasing intention in this segment has been a challenge. Thus, this paper aims to present a mapping of the literature on the attitude toward and intention to purchase generic drugs and capture insights that can help define and improve promotional strategies for the use of these products. To identify articles related to the theme, we selected the Web of Science, Science Direct, Scopus, Lilacs, Pubmed Central, Springer, and Embase databases time limited to June 2020, using the keywords “generic drug”, “purchase intention”, and “attitude”. The results indicate that this topic is relatively new, with publications in the leading journals in the area demonstrating its importance. Analysis revealed five strategic insights and showed that the research theme could be grouped into three clusters: (i) consumer attitude and behavior, (ii) perspective of patients and health professionals, and (iii) assessment of the risks associated with generic medications to determine which factors can influence purchase intention, providing decision makers with a broader view with regard to directing public policy strategies in healthcare.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Attitude and Purchase Intention to Generic Drugs

Arcaro

Veiga

Silva

et al. 2021

IJERPH

View full text Add to dashboard Cite

show abstract

“…Another pharmaceutical industry "Teva UK Limited" developed bio-equivalent product by conducting bioequivalence study against the innovator product. So, the product of Zentiva is innovator and the product of Teva is generic product [5].…”

Section: Innovator and Generic Drug Productsmentioning

confidence: 99%

Development of Generic Drug Products by Pharmaceutical Industries Considering Regulatory Aspects: A Review

Hasan¹,

Shimu²,

Akther³

et al. 2021

JBM

View full text Add to dashboard Cite

Development of generic drug product by pharmaceutical industry is a scientific and technical approach which is totally different from developing a reference or innovator product. Most of the developing countries focus on developing the generic drug products because huge amount of investment is required for innovation and to develop reference product. The generic medicine has to be bioequivalent to the innovator drug and ensure the same biological effect with proper safety and efficacy. Nowadays, the pharmaceutical industries focus on the development of generic product as this does not require that much time and cost compared to the innovator company. But development of generic product is also difficult as it contains the same therapeutic efficacy as innovator. The development approach is based on the target market, i.e. US market, EU market. If a manufacturer targets the US market, then all excipients should be USP grade, analysis should be conducted by USP method or in-house method and stability studies as well. Prior and during the development of generic drug product API selection, dosage form selection, reference product selection and characterization, formulation development, analytical method development, tech transfer or submission batch are prime concern. Then again, bioequivalence study, drug registration procedure and commercialization of the generic product considering regulatory guidance of respective regulatory agencies and the approaches taken by the regulatory agencies for the development of registration of generic medicines are also crucial as well for the development of generic drug product. The aim of this study was to review the entire stage of a generic drug development by a generic pharmaceutical company.

show abstract

“…In terms of differences in the product itself ( Table 2), brand name drugs contain the original combination of the active ingredient and binders that was tested in clinical trials [9]. Brand name drugs often cost at least 50% more than generic [9] but have the advantage of maintaining consistent packaging and therefore are more recognizable to physicians and patients.…”

Section: Differences In Drug Productmentioning

confidence: 99%

“…Brand name drugs often cost at least 50% more than generic [9] but have the advantage of maintaining consistent packaging and therefore are more recognizable to physicians and patients. Generics, however, have the same active molecule but are bound by different excipients and packaged differently [9]. They are more likely to be covered by insurance and are the default medications used in hospital.…”

Section: Differences In Drug Productmentioning

confidence: 99%

Is Brand Name Best? Brand name versus generic pharmaceuticals in clinical practice

A.M.

2017

UOJM

View full text Add to dashboard Cite

Au cours des dernières années, les brevets de certains des plus grands « médicaments vedettes », c'est-à-dire des médicaments qui rapportent des milliards de dollars aux compagnies pharmaceutiques, sont arrivés à échéance. Cela signifie que les fabricants de médicaments génériques peuvent désormais produire ceux-ci à moindre coût. Mais qu'est-ce qui différencie véritablement les mé-dicaments génériques de ceux d'origine? Ce commentaire examinera comment les différences en ce qui a trait aux licences affectent l'efficacité des médicaments, et comment le panorama pharmaceutique au Canada affecte les soins de santé.C o m m e n t a r y

show abstract

A Global Comparison Between Brand-Name and Generic Drugs

Cited by 6 publications

References 30 publications

Attitude and Purchase Intention to Generic Drugs

Attitude and Purchase Intention to Generic Drugs

Development of Generic Drug Products by Pharmaceutical Industries Considering Regulatory Aspects: A Review

Is Brand Name Best? Brand name versus generic pharmaceuticals in clinical practice

Contact Info

Product

Resources

About